Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties.
The widely abused psychostimulant cocaine is thought to elicit its reinforcing effects primarily via inhibition of the neuronal dopamine transporter (DAT). However, not all DAT inhibitors share cocaine's behavioral profile, despite similar or greater affinity for the DAT. This may be due to differential molecular interactions with the DAT. Our previous work using transporter mutants with altered conformational equilibrium (W84L and D313N) indicated that benztropine and GBR12909 interact with the DAT in a different manner than cocaine. Here, we expand upon these previous findings, studying a number of structurally different DAT inhibitors for their ability to inhibit [(3)H]CFT binding to wild-type, W84L and D313N transporters. We systematically tested structural intermediates between cocaine and benztropine, structural hybrids of benztropine and GBR12909 and a number of other structurally heterologous inhibitors. Derivatives of the stimulant desoxypipradrol (2-benzhydrylpiperidine) exhibited a cocaine-like binding profile with respect to mutation, whereas compounds possessing the diphenylmethoxy moiety of benztropine and GBR12909 were dissimilar to cocaine-like compounds. In tests with specific isomers of cocaine and tropane analogues, compounds with 3alpha stereochemistry tended to exhibit benztropine-like binding, whereas those with 3beta stereochemistry were more cocaine-like. Our results point to the importance of specific molecular features--most notably the presence of a diphenylmethoxy moiety--in determining a compound's binding profile. This study furthers the concept of using DAT mutants to differentiate cocaine-like inhibitors from atypical inhibitors in vitro. Further studies of the molecular features that define inhibitor-transporter interaction could lead to the development of DAT inhibitors with differential clinical utility.
Schmitt
Kyle C
KC
Department of Psychiatry, New York University School of Medicine, New York, New York, USA.
Zhen
Juan
J
Kharkar
Prashant
P
Mishra
Manoj
M
Chen
Nianhang
N
Dutta
Aloke K
AK
Reith
Maarten E A
ME
D000818:Animals; D001216:Asparagine / Q000235:genetics; D001224:Aspartic Acid / Q000235:genetics; D001590:Benztropine / Q000737:chemistry / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects*; D002461:Cell Line, Transformed; D003042:Cocaine / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics*; D018765:Dopamine Uptake Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D007930:Leucine / Q000235:genetics; D008958:Models, Molecular; D009154:Mutation / Q000235:genetics*; D010879:Piperazines / Q000737:chemistry / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D017434:Protein Structure, Tertiary; D012964:Sodium / Q000378:metabolism; D013329:Structure-Activity Relationship; D014162:Transfection / Q000379:methods; D014316:Tritium / Q000378:metabolism; D014364:Tryptophan / Q000235:genetics
D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D010879:Piperazines; D014316:Tritium; D001590:Benztropine; D001224:Aspartic Acid; C021279:(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester; D001216:Asparagine; D014364:Tryptophan; C043425:vanoxerine; D012964:Sodium; D007930:Leucine; D003042:Cocaine
Nature. 2007 Aug 23;448(7156):952-6
17687333
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12761-6
17652169
J Neurochem. 2006 Sep;98(5):1531-40
16923164
J Neurochem. 2001 May;77(4):1116-27
11359877
Nat Neurosci. 2008 Jul;11(7):780-9
18568020
J Neurosci. 2001 Mar 1;21(5):1787-94
11222668
Biochem Pharmacol. 2005 Aug 1;70(3):461-9
15950948
J Neurochem. 2004 May;89(3):750-65
15086531
J Biol Chem. 2007 Oct 5;282(40):29441-7
17698848
J Pharmacol Exp Ther. 2005 Aug;314(2):575-83
15879005
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9333-8
16754872
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1683-8
11818545
Eur J Pharmacol. 2004 Dec 3;506(1):17-26
15588620
J Biol Chem. 2007 Mar 23;282(12):8915-25
17255098
J Pharmacol Exp Ther. 2007 Nov;323(2):720-9
17673606
Nature. 2005 Sep 8;437(7056):215-23
16041361
Eur J Pharmacol. 1995 Aug 4;281(2):195-203
7589207
Bioorg Med Chem Lett. 2005 Dec 15;15(24):5488-93
16202585
Eur J Pharmacol. 2003 Oct 31;479(1-3):93-106
14612141
Biophys J. 2007 Nov 15;93(10):3627-39
17704152
Pflugers Arch. 2004 Feb;447(5):519-31
12719981
J Neurosci. 2005 Feb 23;25(8):1889-93
15728828
J Pharmacol Exp Ther. 2006 Jun;317(3):1088-96
16478825
J Med Chem. 1992 Jan;35(1):135-40
1732520
J Biol Chem. 2006 Jan 27;281(4):2012-23
16272152
Mol Pharmacol. 2008 Apr;73(4):1141-50
18216182
J Biol Chem. 1999 Dec 24;274(52):36928-34
10601246
Nature. 1996 Feb 15;379(6566):606-12
8628395
Neuropsychopharmacology. 2006 Feb;31(2):351-62
15957006
J Biol Chem. 2001 Aug 3;276(31):29012-8
11395483
Science. 2007 Sep 7;317(5843):1390-3
17690258
Synapse. 2005 Nov;58(2):72-94
16088952
Mol Pharmacol. 2000 Dec;58(6):1581-92
11093799
Mol Pharmacol. 2008 Mar;73(3):813-23
17978168
Mol Pharmacol. 1999 Aug;56(2):434-47
10419565
Addict Behav. 2004 Sep;29(7):1439-64
15345275
Biochem Pharmacol. 1986 Apr 1;35(7):1123-9
3964292
Pharmacol Biochem Behav. 1982 Nov;17(5):901-4
6817350
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
4202581
Proteins. 2008 Feb 15;70(3):1033-46
17847094
J Neurochem. 2004 May;89(4):853-64
15140185